EGFR and lung cancer: In an early phase II clinical trial for neratinib (NCT00266877), despite disappointing results for EGFR mutant lung cancer overall, three out of four patients with the rare EGFR mutation G719X showed a partial response to neratinib, whilst the fourth exhibited stable disease for 40 weeks [21].